SEC Form 4
Artiva Biotherapeutics, Inc. (ARTV) insider trading
In the 12 months to Oct 26, 2026, 2 ARTV insiders reported open-market sales of $569.2K across 6 filings; 3 insiders bought $109.1M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $569.2K
- 6 filings · 2 insiders
- Open-market purchases
- $109.1M
- 14 filings
- Pre-arranged sales (10b5-1)
- 6 of 6
- All $569.2K sold was pre-arranged
Who traded ARTV, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
ARTV daily close from Oct 27, 2025 to Oct 26, 2026, between $3.07 and $13.39, last $6.18. 6 sale and 14 purchase filings by 5 insiders, marked at their filing dates. Rajeev M. Shah, Director: bought $88.3M across 8 filings, first filed May 13, 2026, last Jul 31, 2026. GC Corp., 10% owner: bought $16.5M across 1 filing, first filed May 28, 2026, last May 28, 2026. Peter Kolchinsky, Director: bought $4.3M across 5 filings, first filed Jun 16, 2026, last Jul 28, 2026. Fred Aslan, President and CEO → Chief Executive Officer: sold $465.3K across 4 filings, first filed Nov 17, 2025, last Oct 7, 2026. Subhashis Banerjee, Chief Medical Officer: sold $103.9K across 2 filings, first filed Aug 19, 2026, last Aug 31, 2026.
Largest mark · tap a row for others
Rajeev M. Shah · Director
Purchase $74,999,992
6,510,416 shares at $11.52 avg
Filed May 13, 2026 · traded May 11
Close on filing date $10.50
Rajeev M. Shah · Director
Director
$88.3M boughtGC Corp. · 10% owner
10% owner
$16.5M boughtPeter Kolchinsky · Director
Director
$4.3M boughtFred Aslan · President and CEO → Chief Executive Officer
President and CEO → Chief Executive Officer
$465.3K soldSubhashis Banerjee · Chief Medical Officer
Chief Medical Officer
$103.9K soldOpen-market trades
20 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Rajeev M. Shah | Director | — | $88.3M | 8 | — | |
| GC Corp. | 10% owner | — | $16.5M | 1 | — | |
| Peter Kolchinsky | Director | — | $4.3M | 5 | — | |
| Fred Aslan | President and CEO → Chief Executive Officer | $465.3K | — | 4 | 100% of sales | |
| Subhashis Banerjee | Chief Medical Officer | $103.9K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Fred Aslan Chief Executive Officer | SalePre-arranged (10b5-1) | 23,463 | $7.20 | $168.9K | 1,519,606 | |
traded | Fred Aslan Chief Executive Officer | SalePre-arranged (10b5-1) | 23,429 | $10.92 | $255.7K | 1,449,765 | |
traded | Subhashis Banerjee Chief Medical Officer | SalePre-arranged (10b5-1) | 8,222 | $12.01 | $98.7K | 142,047 | |
traded | Subhashis Banerjee Chief Medical Officer | SalePre-arranged (10b5-1) | 429 | $12.00 | $5.1K | 144,963 | |
traded | Rajeev M. Shah Director | Purchase | 45,768 | $9.96 | $455.7K | 17,329,570 | |
traded | Peter Kolchinsky Director | Purchase | 41,319 | $9.99 | $412.8K | 17,283,802 | |
traded | Rajeev M. Shah Director | Purchase | 6,522 | $8.94 | $58.3K | 16,817,543 | |
traded | Peter Kolchinsky Director | Purchase | 264,586 | $9.76 | $2.6M | 17,242,483 | |
traded | Peter Kolchinsky Director | Purchase | 7,882 | $8.95 | $70.5K | 16,977,927 | |
traded | Rajeev M. Shah Director | Purchase | 152,472 | $8.93 | $1.4M | 16,970,045 | |
traded | Rajeev M. Shah Director | Purchase | 15,102 | $8.97 | $135.5K | 16,811,021 | |
traded | Rajeev M. Shah Director | Purchase | 31,000 | $8.88 | $275.3K | 16,794,043 | |
traded | Peter Kolchinsky Director | Purchase | 1,876 | $8.98 | $16.8K | 16,795,919 | |
traded | Peter Kolchinsky Director | Purchase | 140,307 | $8.90 | $1.2M | 16,763,043 | |
traded | Rajeev M. Shah Director | Purchase | 391,019 | $8.57 | $3.4M | 16,622,736 | |
traded | Rajeev M. Shah Director | Purchase | 1,027,722 | $7.44 | $7.7M | 16,231,717 | |
traded | GC Corp. 10% owner | Purchase | 1,432,291 | $11.52 | $16.5M | Multiple accounts | |
traded | Rajeev M. Shah Director | Purchase | 6,510,416 | $11.52 | $75.0M | 15,203,995 | |
traded | Fred Aslan President and CEO | SalePre-arranged (10b5-1) | 3,187 | $6.00 | $19.1K | 1,209,948 | |
traded | Fred Aslan President and CEO | SalePre-arranged (10b5-1) | 6,375 | $3.38 | $21.5K | 343,999 |
GET /stocks/filings/vX/form-4?tickers=ARTV&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ARTV"
],
"issuer_cik": "0001817241",
"owner_cik": "0001909362",
"accession_number": "0001193125-26-416953",
"form_type": "4",
"filing_date": "2026-10-07",
"period_of_report": "2026-10-06",
"issuer_name": "Artiva Biotherapeutics, Inc.",
"issuer_trading_symbol": "ARTV",
"owner_name": "Aslan Fred",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-06",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 23463,
"transaction_price_per_share": 7.1977,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1519606,
"transaction_value": 168879.6351,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026."
},
{
"id": "F2",
"description": "The weighted average sale price for the transaction reported was $7.1977, and the range of prices were between $6.92 and $7.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."
}
]
},
{
"tickers": [
"ARTV"
],
"issuer_cik": "0001817241",
"owner_cik": "0001909362",
"accession_number": "0001193125-26-386431",
"form_type": "4",
"filing_date": "2026-09-09",
"period_of_report": "2026-09-08",
"issuer_name": "Artiva Biotherapeutics, Inc.",
"issuer_trading_symbol": "ARTV",
"owner_name": "Aslan Fred",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-08",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 23429,
"transaction_price_per_share": 10.9158,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1449765,
"transaction_value": 255746.27820000003,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026."
},
{
"id": "F2",
"description": "The weighted average sale price for the transaction reported was $10.9158, and the range of prices were between $10.72 and $11.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 41 records
- Option exercises2 records
- Tax withholding9 records
- Tax withholding (sold to cover)13 records
- Grants and awards17 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Artiva Biotherapeutics, Inc.'s CEO sold stock?
Yes. Fred Aslan (CEO) sold 56,454 shares ($465.3K) between Nov 2025 and Oct 2026, all under a pre-arranged 10b5-1 plan.
How current is ARTV’s insider data?
These are ARTV Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ARTV insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ARTV every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.